DiaMedica Therapeutics Inc. (DMAC) EBIT Margin (2018)
DiaMedica Therapeutics (DMAC) has 1 years of EBIT Margin data on record, last reported at 297.6% in Q3 2018.
- For Q3 2018, EBIT Margin changed N/A year-over-year to 297.6%; the TTM value through Jun 2019 reached 1953.4%, changed N/A, while the annual FY2024 figure was 78473.53%, 1819465.0% down from the prior year.
- EBIT Margin reached 297.6% in Q3 2018 per DMAC's latest filing.
- Across five years, EBIT Margin topped out at 297.6% in Q3 2018 and bottomed at 297.6% in Q3 2018.